Board of Directors
|
Batsheva Elran Chairperson |
Founder and Managing Partner, Opal Ventures. Ms. Elran is one of the founders of the Israeli Healthcare Venture Capital Industry with over 20 years of business experience. Prior to that, Ms. Elran was a legal advisor with the anti-trust authorities and an attorney, specializing in intellectual property and business law litigation. Currently, a Managing Partner of Medica3, a $115M healthcare venture fund, building and investing in companies including Remon Medical, acquired by Boston Scientific and Ventor Technologies, acquired by Medtronic. A chairperson of Expanding Orthopedics Inc and Endymed Ltd. and a board members of IC Green Ltd. Multidisciplinary background in healthcare, investments management and business law. Ms. Elran has a B.Sc. cum laude in Pharmacy, the Hebrew University, a LL.B. the University of Tel-Aviv and an Executive MBA, University of Bradford, UK and she is a certified board member. |
|
Gavin B. Samuels Director | Gavin Samuels, is a Senior Director for Teva Innovative Ventures, the proprietary division of Teva Pharmaceuticals. In this role he is responsible for identifying and investing in or licensing early stage compounds from small biotech companies and academic institutions. Before joining Teva, he worked at Quark Pharmaceuticals as Senior Vice President, Business Development & Investor Relations. Prior to this Gavin held positions at Pfizer (2000-2006) and Merck & (1998-2000) including Worldwide Business Development, Strategic Investments and product development. Gavin obtained his medical degree from the University of Witwatersrand, South Africa, an M.B.A. from the University of New England, Australia and a degree in Health Economics from Monash University, Australia |
|
Morris Laster, MD Director |
A leading Israeli biotechnology manager and entrepreneur. Dr. Laster served as Director and Chief Executive Officer of BioLineRx (TASE: BLRX) since its inception in 2003 until December 2009, and continued to serve on its board until 2010. Prior to that, Dr. Laster served as Chairman and Chief Executive Officer of Keryx Biopharmaceuticals Inc. (NASDAQ: KERX; AIM: KRX), from 1997 to 2001, and as its Chairman until 2002. Dr. Laster has also been associated with several other public companies, including Neose Technologies, Inc., XTL biopharmaceuticals Ltd. (TASE: XTL) and Progenitor Inc. In addition, Dr. Laster is also a member of the BOD CGM3, a medical device start-up company. From 1990 to 1996, Dr. Laster was employed as Vice President of Medical Venture Capital with Paramount Capital Investments LLC. Dr. Laster holds an M.D. from Downstate Medical Center in New York and a B.Sc. in Biology from State University of New York in Albany, New York. He carried out post graduate work in surgery at Case Western Reserve University Hospital in Ohio and served as a physician and officer with the Paratroopers corps of the Israeli Defense Forces. |
|
Oren M. Becker, PhD Director |
President and CEO, Founder, Dynamix Pharmaceuticals |
Board of Directors